The ongoing COVID-19 pandemic, the war in Ukraine, rising fuel costs, manufacturing concerns and the ripple of other global events have led to supply chain issues across the world that, in the United States, has been most recently highlighted by a shortage of baby formula.
Just as Emergent BioSolutions looked to be making some headway in course corrections following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine, new information indicates the Maryland-based company sought to hide the deficiencies from federal regulators, all while touting its manufacturing capabilities, according to a BioSpace article.
Novavax Inc.’s shares plunged nearly 20 percent in premarket trading on May 10 due to uncertainty over global demand for the company’s COVID-19 vaccine following a slow start to deliveries.
Europe’s first “blank cheque” company focused on acquiring companies that make medicines for the biotech and pharmaceutical industry launched on May 9, with plans to raise 150 million euros.
Ferrero on April 12 asked U.S. consumers to dispose of some Kinder chocolate products not authorized for distribution in the country, warning they could be from the batch recently recalled in Europe due to a potential Salmonella Typhimurium contamination.
TANAKA Kikinzoku Kogyo K.K., which operates the TANAKA Precious Metals manufacturing business, announced that TANAKA developed gold shell nanoparticles1 that can be prepared in high concentrations using high dispersion stability.
Pfizer Inc. now expects to manufacture 80 million treatment courses of the company’s experimental COVID-19 antiviral drug, up from a previous forecast of 50 million, Chief Executive Officer Albert Bourla said in a CNBC interview on November 29.
Novartis agreed to expand the company’s fill-and-finish support for the Pfizer/BioNTech Covid-19 vaccine by using manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022, the Swiss drugmaker said on Oct. 21.
Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.
CureVac said on Sept. 14 the German biotech firm cancelled contract manufacturing deals for the company’s experimental Covid-19 vaccine with two prospective partners, after rivals with approved shots boosted production.